BACKGROUND: Regulatory macrophages play an important role in wound healing and gut homeostasis and have antiinflammatory properties. Induction of this cell type (Mψ(ind) ) by the anti-tumor necrosis factor (TNF) antibodies, infliximab and adalimumab, has recently been shown in vitro. Also, the superiority of infliximab/azathioprine combination therapy over infliximab or azathioprine monotherapy has recently been established, but the mechanism behind this remains unclear. The aim of this study was to examine the induction of regulatory macrophages in patients with and without mucosal healing in response to infliximab. In addition, we studied the effect of infliximab/azathioprine combination treatment on the differentiation and function of regulatory macrophages. METHODS: Inflammatory bowel disease (IBD) patients (n = 10) underwent endoscopy before and after first infliximab treatment. Immunohistochemical staining of CD68 and CD206 was performed in all patients. Mixed lymphocyte reactions (MLRs) were treated with infliximab, azathioprine, or both. Macrophage phenotype was evaluated by flow cytometry and inhibition of T-cell proliferation was measured in a secondary MLR containing macrophages and third-party lymphocytes. RESULTS: A significant induction of regulatory macrophages was observed in patients with mucosal healing after treatment with infliximab; this induction was absent in patients without mucosal healing. In addition, Mψ(ind) have the ability to induce wound healing in an in vitro model, further suggesting a key role for infliximab-induced macrophages in mucosal healing. Upon infliximab/azathioprine combination treatment, an increased number of regulatory macrophages was observed. These macrophages also displayed stronger immunosuppressive properties than macrophages induced by infliximab monotherapy. CONCLUSIONS: These data show that regulatory macrophages may be involved in mucosal healing and provide a rationale for the superiority of infliximab/azathioprine combination treatment observed in the clinic.
BACKGROUND: Regulatory macrophages play an important role in wound healing and gut homeostasis and have antiinflammatory properties. Induction of this cell type (Mψ(ind) ) by the anti-tumor necrosis factor (TNF) antibodies, infliximab and adalimumab, has recently been shown in vitro. Also, the superiority of infliximab/azathioprine combination therapy over infliximab or azathioprine monotherapy has recently been established, but the mechanism behind this remains unclear. The aim of this study was to examine the induction of regulatory macrophages in patients with and without mucosal healing in response to infliximab. In addition, we studied the effect of infliximab/azathioprine combination treatment on the differentiation and function of regulatory macrophages. METHODS:Inflammatory bowel disease (IBD) patients (n = 10) underwent endoscopy before and after first infliximab treatment. Immunohistochemical staining of CD68 and CD206 was performed in all patients. Mixed lymphocyte reactions (MLRs) were treated with infliximab, azathioprine, or both. Macrophage phenotype was evaluated by flow cytometry and inhibition of T-cell proliferation was measured in a secondary MLR containing macrophages and third-party lymphocytes. RESULTS: A significant induction of regulatory macrophages was observed in patients with mucosal healing after treatment with infliximab; this induction was absent in patients without mucosal healing. In addition, Mψ(ind) have the ability to induce wound healing in an in vitro model, further suggesting a key role for infliximab-induced macrophages in mucosal healing. Upon infliximab/azathioprine combination treatment, an increased number of regulatory macrophages was observed. These macrophages also displayed stronger immunosuppressive properties than macrophages induced by infliximab monotherapy. CONCLUSIONS: These data show that regulatory macrophages may be involved in mucosal healing and provide a rationale for the superiority of infliximab/azathioprine combination treatment observed in the clinic.
Authors: Raymond A Isidro; Abdon Lopez; Myrella L Cruz; Mayra I Gonzalez Torres; Gladys Chompre; Angel A Isidro; Caroline B Appleyard Journal: J Histochem Cytochem Date: 2017-07-10 Impact factor: 2.479
Authors: N Nazareth; F Magro; J Silva; M Duro; D Gracio; R Coelho; R Appelberg; G Macedo; A Sarmento Journal: Clin Exp Immunol Date: 2014-09 Impact factor: 4.330
Authors: Franz Kratochvill; Geoffrey Neale; Jessica M Haverkamp; Lee-Ann Van de Velde; Amber M Smith; Daisuke Kawauchi; Justina McEvoy; Martine F Roussel; Michael A Dyer; Joseph E Qualls; Peter J Murray Journal: Cell Rep Date: 2015-09-10 Impact factor: 9.423
Authors: Alon D Levin; Pim J Koelink; Felicia M Bloemendaal; Anne Christine W Vos; Geert R D'Haens; Gijs R van den Brink; Manon E Wildenberg Journal: J Crohns Colitis Date: 2015-09-27 Impact factor: 9.071
Authors: Emilio G Quetglas; Zlatan Mujagic; Simone Wigge; Daniel Keszthelyi; Sebastian Wachten; Ad Masclee; Walter Reinisch Journal: World J Gastroenterol Date: 2015-11-28 Impact factor: 5.742